Fresenius Medical Care AG & Co. KGaA
FMS | NYSE
$22.47
-$0.66 (-2.85%)
At close: Oct 30, 2026, 4:00 PM ET
$22.69
+$0.22 (+0.98%)
Pre-market:
Nov 2, 2026, 9:28 AM ET
Company Profile
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
Key Executives
| Name | Position |
|---|---|
| Cassie McLean | Chief Executive Officer of Care Delivery & Member of Management Board |
| Craig Cordola FACHE | Chief Executive Officer of Care Delivery & Member of Management Board |
| Helen Giza | Chair of Management Board & Chief Executive Officer |
| Joseph E. Turk Jr. | Chief Executive Officer of Care Enablement & Member of Management Board |
| Martin Fischer | Chief Financial Officer & Member of the Management Board |
| Charles Hugh-Jones | Global Chief Medical Officer & Member of Management Board |
| Dominik Heger | Executive Vice President and Head of Investor Relations, Strategic Development & Communications |
| Gail-Suzanne Brown | Senior Vice President of Research & Development |
| Glenn Slater | Senior Vice President of Manufacturing and Supply Chain Operations |
| Joachim Weith | Senior Vice President of Corporate Communications & Governmental Affairs |
| Jorg Haring | Member of the Management Board, Global Head of Legal,Compliance & Human Resources and Labor Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 25, 2026 | 6-K | Filing |
| Aug 27, 2026 | 6-K | Filing |
| Aug 24, 2026 | SC 13D/A | [Amend] Filing |
| Aug 04, 2026 | 6-K | Filing |
| Aug 03, 2026 | 6-K | Filing |
| Aug 03, 2026 | 6-K | Filing |
| Aug 03, 2026 | 6-K | Filing |
| Jul 29, 2026 | 6-K | Filing |
| Jul 28, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jun 29, 2026 | 11-K | Filing |
Fresenius Medical Care AG & Co. KGaA
| Country | Germany |
| IPO Date | Sep 17, 1996 |
| Industry | Medical - Care Facilities |
| Sector | Healthcare |
| Employees | 108,165 |
| CEO | Helen Giza |
Contact Details
Else-KrOener Strasse 1 Bad Homburg,
HE 61352 Germany
Stock Details
| Ticker Symbol | FMS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001333141 |
| CUSIP Number | 358029106 |
| ISIN Number | US3580291066 |
| SIC Code | 8090 |
Recent News
- 10 days ago / zacks.comFMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI
- 12 days ago / prnewswire.comFresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™
- 12 days ago / businesswire.comFly Alliance to Replace Entire Flight Management System with flyExclusive's AI-Powered Contrails FMS
- 14 days ago / prnewswire.comFresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026
- 26 days ago / zacks.comReasons to Retain Fresenius Medical Stock in Your Portfolio for Now
- 1 month ago / zacks.comFresenius Medical Care Reshapes China Portfolio for Long-Term Growth
- 1 month ago / prnewswire.comFresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership
- 2 months ago / zacks.comCan Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?
- 3 months ago / youtube.com3 Cheap International Stocks to Buy
- 3 months ago / zacks.comFMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand
Add to Watchlist
Select watchlists to add or remove FMS